厄贝沙坦联合美托洛尔治疗慢性充血性心衰的临床分析

Clinical Analysis of Irbesartan Combined With Metoprolol in the Treatment of Chronic Congestive Heart Failure

目的观察厄贝沙坦联合美托洛尔治疗慢性充血性心衰的临床效果。方法选取2014年1月-2017年9月在我院接受治疗的58例慢性充血性心衰患者作为研究对象。以治疗方法为依据,将患者分成对照组与观察组,每组各29例。对照组患者采用厄贝沙坦治疗,观察组患者采用厄贝沙坦联合美托洛尔治疗,比较治疗后两组患者的临床效果。结果治疗后观察组患者NYHA、LVEDD、LVEF情况明显优于对照组,且两组之间差异具有统计学意义(P<0.05)。结论厄贝沙坦联合美托洛尔治疗慢性充血性心衰效果更明显,值得临床推广。

Objective To observe the clinical effect of irbesartan combined with metoprolol in the treatment of chronic congestive heart failure. Methods 58 patients with chronic congestive heart failure who were treated in our hospital from January 2014 to September 2017 were selected as the subjects. According to the treatment method, the patients were divided into control group and observation group, each group of 29 cases. The control group of patients with irbesartan treatment, observation group of patients with irbesartan combined with metoprolol treatment, the clinical effect of two groups was compared. Results After treatment, the levels of NYHA, LVEDD and LVEF in the observation group were significantly better than those in the control group, and the difference between the two groups was statistically significant（P〈0.05）. Conclusion Irbesartan combined with metoprolol in the treatment of chronic congestive heart failure is more obvious, worthy of clinical promotion.